Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Ho

Showing results (111-120 of 241) with videos related to

Pageof 25
Sort By:
Plos Medicine|November 16, 2006
Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of ChinaYong Zhang, Lin Lu, Lei Ba, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitorsSho Iketani, Farhad Forouhar, Hengrui Liu, et al.
AIDS (London, England)|December 1, 2016
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251Chasity D Andrews, Leslie St Bernard, Amanda Yee Poon, et al.
Science (New York, N.Y.)|September 28, 2002
Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factorLinqi Zhang, Wenjie Yu, Tian He, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutininMing-Wei Chen, Hsin-Yu Liao, Yaoxing Huang, et al.
Science (New York, N.Y.)|March 6, 2014
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusChasity D Andrews, William R Spreen, Hiroshi Mohri, et al.
Emerging Microbes & Infections|May 23, 2024
SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1Qian Wang, Yicheng Guo, Logan T Schwanz, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2021
Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing AntibodiesGabriele Cerutti, Micah Rapp, Yicheng Guo, et al.
The Journal of Applied Laboratory Medicine|October 30, 2023
The "Bubble": What Can Be Learned from the National Basketball Association (NBA)'s 2019-20 Season Restart in Orlando during the COVID-19 PandemicChristina D Mack, Michael H Merson, Leroy Sims, et al.
Vaccines|December 18, 2020
Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion PeptideAlemu Tekewe Mogus, Lihong Liu, Manxue Jia, et al.
Pageof 25

Showing results (111-120 of 241) with videos related to

Sort By:
Pageof 25
Plos Medicine|November 16, 2006
Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of ChinaYong Zhang, Lin Lu, Lei Ba, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitorsSho Iketani, Farhad Forouhar, Hengrui Liu, et al.
AIDS (London, England)|December 1, 2016
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251Chasity D Andrews, Leslie St Bernard, Amanda Yee Poon, et al.
Science (New York, N.Y.)|September 28, 2002
Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factorLinqi Zhang, Wenjie Yu, Tian He, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutininMing-Wei Chen, Hsin-Yu Liao, Yaoxing Huang, et al.
Science (New York, N.Y.)|March 6, 2014
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusChasity D Andrews, William R Spreen, Hiroshi Mohri, et al.
Emerging Microbes & Infections|May 23, 2024
SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1Qian Wang, Yicheng Guo, Logan T Schwanz, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2021
Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing AntibodiesGabriele Cerutti, Micah Rapp, Yicheng Guo, et al.
The Journal of Applied Laboratory Medicine|October 30, 2023
The "Bubble": What Can Be Learned from the National Basketball Association (NBA)'s 2019-20 Season Restart in Orlando during the COVID-19 PandemicChristina D Mack, Michael H Merson, Leroy Sims, et al.
Vaccines|December 18, 2020
Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion PeptideAlemu Tekewe Mogus, Lihong Liu, Manxue Jia, et al.
Pageof 25